TB-500 and the Prescription Route in the United States

The short answer first: there is no FDA-approved TB-500 drug product. No sponsor has obtained approval of a marketing application for it, so no clinician in the United States can write a prescription for an approved TB-500 medicine, in the way they would for an approved antibiotic or an approved hormone. Anyone who tells you TB-500 is an approved prescription drug is wrong.

What changed in late 2026 is narrower, and it is worth stating precisely. On October 28, 2026, the U.S. Department of Health and Human Services issued an enforcement discretion policy covering the use of certain peptide bulk drug substances in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. A notice announcing the policy was published in the Federal Register on October 30, 2026 (Vol. 91, No. 209, page 68526) under docket number HHS-OASH-2026-0496. TB-500 is one of six peptides addressed.

Under that policy, HHS states that it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility, or a licensed physician that compounds a preparation using TB-500 acetate for subcutaneous or intramuscular administration, when all of the circumstances described in the policy are present. Two words carry most of the weight here. "Enforcement discretion" is a statement about how an agency intends to deploy its own resources; it is not a change in the underlying law, and a compounded preparation remains an unapproved drug. "All" means the conditions are cumulative: miss one and the policy, by its own terms, does not apply.

This article deals with one question only: the prescription and pharmacy-compounding route for TB-500 in the United States, as described in the primary documents. It does not restate what the molecule is or what the preclinical literature does and does not show. For that background, see the general TB-500 guide. For how peptide rules differ across jurisdictions, see are peptides legal, and for the safety framing, are peptides safe.

Educational purposes only. Nothing below is medical advice, and nothing below should be read as encouragement to obtain or use an unapproved substance. Consult a licensed healthcare professional.

The policy document is titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It describes how HHS intends to approach compounding with a short list of peptide bulk drug substances while the 503A bulk drug substances list is being developed through rulemaking. In other words, it is a holding position taken in the gap between an advisory process that has already happened and a rule that has not yet been issued.

Appendix A of the policy names the substances in scope: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Appendix B then does something more specific and more consequential for readers: it sets out, for each substance, the exact chemical identity and the permitted route of administration, together with the justification for including it. For TB-500, Appendix B specifies the acetate salt of the acetylated actin-binding fragment, with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH · CH₃COOH, molecular formula C₃₈H₆₈N₁₀O₁₄ · CH₃COOH and a molecular weight of about 949.1 g/mol, and limits the covered route to subcutaneous or intramuscular administration.

That identity statement matters more than it looks. A material sold under the name "TB-500" that is in fact a different fragment, a different salt form or a different degree of modification is not the substance described in Appendix B, and a preparation made from it is outside the policy even if every other box is ticked. The name on a label is not an identity; the identity is the structure, confirmed by testing.

HHS also explains its reasoning. The policy is framed as a way to discourage the continued, widespread use of research-use-only peptides supplied by foreign manufacturers that HHS considers a safety risk to U.S. patients, by offering what the agency calls a more controlled alternative. The practical implication is that HHS is contrasting two situations, one inside a licensed pharmacy with documented sourcing and one outside it, and is not endorsing the substance itself.

Finally, the notice opened a comment period running two weeks from publication, that is until November 13, 2026, and the policy states that it does not establish rights for any person and is not binding on HHS or on the public. A draft policy with a two-week comment window is a moving object, and readers should treat any summary, including this one, as a snapshot rather than a settled rule.

The policy lists ten conditions, and enforcement discretion is described as available only when all of them are satisfied. They are summarized below in plain terms. The authoritative wording is in the policy document itself, which is linked in the sources.

Three of these deserve emphasis because they are the ones most often lost in summaries. First, the prescription must be for an identified individual patient. Section 503A compounding is patient-specific by design; it is not a license to produce stock for general distribution, and the labeling condition in item 6 reinforces that by stating on the container itself that the preparation is not for resale.

Second, reporting runs upward. Serious adverse events and product quality problems are to be reported to the FDA, through the MedWatch program, and to relevant state authorities. For a patient, this is one of the few concrete benefits of the regulated route over the unregulated one: a problem has somewhere to go, and the agency can see a pattern forming. The 2026 policy expressly ties its own continuation to that signal.

Third, the conditions are a documentation regime, not a clinical one. None of them says that TB-500 works, that it is safe, or that any particular person should receive it. They describe what must be true about the ingredient, the paperwork, the container and the prescription. The clinical judgment stays entirely with the prescriber, who is making it about an unapproved substance.

Appendix B sets the testing standard, and it is the part of the policy that most directly separates a compliant supply chain from a nominally similar one. A certificate of analysis that simply reports a single purity figure does not meet the standard. The appendix contemplates a lot-specific document reporting, among other things, identity, assay, impurities, residual solvents, elemental impurities, bioburden and bacterial endotoxins.

Each of those categories answers a different question. Identity asks whether the material is the structure named in Appendix B rather than a near neighbor. Assay asks how much of it is present. The impurity, residual solvent and elemental impurity sections ask what else came along from synthesis and purification. Bioburden and endotoxin testing ask whether the starting material is suitable for something that will be injected. A "99% pure" claim with no accompanying detail leaves the last four questions unanswered, and for an injectable preparation those are not minor questions.

There is a scientific reason the policy is built this way. For synthetic peptides, process-related and product-related impurities are not merely inert filler: a review by De Groot and colleagues in Drug Discovery Today (2023) describes how peptide-related impurities can elicit unwanted immune responses, and sets out a framework for assessing that risk for bioactive peptide products. This is why regulators treat the impurity profile, and not just the headline purity number, as a quality attribute. For TB-500 specifically, no such assessment has been completed through an approval process, which is precisely the gap the conditions try to narrow at the ingredient level.

The sourcing conditions work alongside the certificate. The establishment supplying the bulk substance must be registered with the FDA, the original manufacturer must also be registered and must manufacture in conformity with CGMP, and that manufacturer's location must appear on the certificate of analysis. The effect of naming the location is traceability: it makes it possible to tell where the material was actually made rather than where it was last repackaged or relabeled.

For a reader trying to assess a real-world situation, the practical test is simple and does not require chemistry training. Ask whether a lot-specific certificate exists, whether it names the original manufacturing site, and whether it reports the categories listed above rather than a lone purity percentage. If a pharmacy cannot answer those questions about the lot used in a specific preparation, the conditions of the policy are not demonstrably met.

Two of the ten conditions quietly exclude some of the most common formats seen in the informal peptide market. The first is the single active pharmaceutical ingredient requirement. A compounded preparation covered by the policy contains one active ingredient. A combination preparation, for example TB-500 together with another peptide in the same vial, has two, and therefore does not satisfy that condition. Whatever one thinks of combinations scientifically, under this policy a blend is simply not in scope.

There is a coherent regulatory logic to that. With a single active ingredient, a problem can be attributed: if a lot fails testing or a patient has a serious reaction, there is one substance, one certificate of analysis and one impurity profile to examine. With two or more, attribution becomes guesswork, and the reporting condition in the policy loses much of its value. The policy's own risk framing, lot-level testing plus single-ingredient products plus MedWatch reporting, only holds together if each element is present.

The second exclusion comes from the device condition. The policy states that the only drug delivery device co-packaged with, or containing, the compounded preparation is an FDA 510(k)-cleared syringe. On a plain reading of that sentence, a pre-filled pen is not a syringe cleared through the 510(k) pathway, and a preparation supplied in a pen would therefore sit outside the policy. We state this as a reading of the text rather than as an HHS pronouncement about pens, because the text speaks about syringes and does not separately discuss pen injectors.

The distinction is not merely formal. A pen is a metering device: it combines a container, a mechanism and a delivery claim, and its performance characteristics are part of what a regulator would otherwise evaluate. A cleared syringe is a far simpler object with a known regulatory history. Narrowing the permitted device to one well-characterized category reduces the number of unknowns HHS is tolerating at once.

The takeaway for readers is modest but concrete. If a preparation described as compliant with the 2026 policy arrives as a multi-peptide blend, or in a pen rather than with a cleared syringe, then at least one condition of the policy is not met, and the enforcement discretion HHS described does not apply to it on its face. For broader context on how formats and jurisdictions interact, see our overview of peptide legality.

It is neither, and this is the single most misreported aspect of the policy. The documents are explicit: the policy does not add these substances to the 503A bulk drug substances list, and it does not constitute FDA approval of any compounded preparation. It also does not eliminate any other applicable federal or state requirement. A preparation made under it remains an unapproved drug that has not been evaluated by the FDA for safety or effectiveness for any use.

The regulatory history behind the policy underlines the point. For each of the peptides in Appendix A, FDA's Center for Drug Evaluation and Research recommended against listing the substance. The agency's Pharmacy Compounding Advisory Committee then voted in favor of listing six of the peptides it reviewed at its July 2026 meeting, including TB-500. Advisory committee votes are recommendations and are not binding on the FDA. So the current position rests on an advisory vote that ran contrary to the scientific review center's own recommendation, with the formal rulemaking still pending. That is an unusual foundation, and readers are entitled to weigh it as such.

The policy is also temporary by design. It describes itself as reflecting HHS's current exercise of enforcement discretion while the bulks list is developed through rulemaking, and HHS states that it may revisit the policy if it identifies a safety signal or if product quality issues arise with a product in scope. A policy that can be withdrawn on the strength of accumulating reports is not a stable regulatory status, and it should not be planned around as though it were.

Nor does the policy create any entitlement. It states that it does not establish rights for any person and is not binding on HHS or the public. A pharmacy relying on it is making a judgment about enforcement risk, not operating under a permission. A patient relying on it is receiving an unapproved preparation, with the ordinary consequences that follow: no approved labeling, no approved indication, and no finding by the FDA that benefit outweighs risk.

Put plainly: the 2026 policy changes the enforcement posture around how TB-500 acetate may be compounded. It says nothing whatsoever about whether TB-500 works. Those are different questions, and the evidence question is addressed in the main TB-500 guide.

Research-use-only material is not covered. This is the inverse of the policy's stated purpose. HHS frames the policy as a way to discourage the continued, widespread use of research-use-only peptides supplied by foreign manufacturers, which it describes as posing a safety risk to U.S. patients. Material labeled for research use only is, by its own labeling, not intended for administration to people, and nothing in the policy extends any protection or legitimacy to it.

503B outsourcing facilities are not covered. The policy addresses compounding under section 503A, which is patient-specific compounding by state-licensed pharmacies, federal facilities and licensed physicians. It does not independently extend enforcement discretion to outsourcing facilities operating under section 503B, which work under a different statutory framework with different requirements.

Nothing outside the United States changes. This is a U.S. federal enforcement policy issued by HHS under a U.S. statute. It has no effect on the European Union, the United Kingdom, Canada, Australia or anywhere else, and it does not make importation into another country lawful. Readers outside the United States should assume their own national rules apply unchanged, and should start from the jurisdiction-by-jurisdiction picture rather than from U.S. headlines.

State law still applies in full. The tenth condition says so directly: all other applicable requirements must be met. State pharmacy boards set their own rules on compounding, record-keeping, prescribing relationships and telemedicine, and a state may be more restrictive than the federal enforcement posture. Federal enforcement discretion does not pre-empt a state restriction.

And the policy says nothing about clinical appropriateness. It does not establish an indication, a patient population or a monitoring plan, because enforcement policies do not do those things. Anyone considering an unapproved substance should read the safety framing in are peptides safe and discuss it with a licensed clinician who can review their history, medications and reasons for interest. This article is educational and is not a recommendation to use TB-500.

If you are evaluating the regulated route in the United States, the useful questions are factual and verifiable. They are not about outcomes, which nobody can promise for an unapproved substance; they are about whether the conditions HHS described are genuinely met in your specific case.

Questions for the clinician:

• Do you consider TB-500 an unapproved drug, and can you explain how you weigh that in your own judgment?
• What is your reasoning for considering it in my situation, and what are the alternatives, including approved options and doing nothing?
• Is the prescription written for me as an identified individual patient, as the policy requires?
• What would you monitor, what would make you stop, and how would you handle a problem?
• How would a serious adverse event be reported to the FDA and to the state, and who files that report?
• Are you aware that FDA's Center for Drug Evaluation and Research recommended against listing this peptide, and that the HHS policy is temporary?

Questions for the pharmacy:

• Is the preparation made from TB-500 acetate matching the identity specified in HHS Appendix B, for subcutaneous or intramuscular administration?
• Can you provide the lot-specific certificate of analysis for the material used in my preparation?
• Does that certificate name the original manufacturer and its manufacturing location, and is that manufacturer registered with the FDA and compliant with CGMP?
• Does the certificate report identity, assay, impurities, residual solvents, elemental impurities, bioburden and bacterial endotoxins, rather than a purity percentage alone?
• Does the preparation contain a single active ingredient?
• Will the labeling carry the statement "This is a compounded drug product. Not for resale."?
• Is the only device supplied with it an FDA 510(k)-cleared syringe?
• Are you a state-licensed pharmacy compounding under section 503A, and are you relying on the HHS policy of October 28, 2026?

A straightforward answer to each of those is what compliance with the policy looks like in practice. Evasiveness on the certificate of analysis, on the original manufacturing site, or on the single-ingredient condition tells you that the situation in front of you is not the situation HHS described.

Medical disclaimer. This article is for educational purposes only, reflects the primary documents as published, and is not medical, pharmaceutical or legal advice. TB-500 is not approved by the FDA for any use. Consult a licensed healthcare professional before making any health decision, and do not treat an enforcement discretion policy as evidence of safety or effectiveness.